In adults with moderate to severe methamphetamine use disorder (339 treated), mirtazapine reduced use days over 12 weeks more than placebo (7.0 vs 4.8 fewer days of 28). Drowsiness (47% vs 33%) and weight gain (10% vs 3%) were more common; secondary end points did not differ.
RCTn = 344
McKetin et al. Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial